{"id":423,"date":"2024-10-23T13:06:05","date_gmt":"2024-10-23T13:06:05","guid":{"rendered":"https:\/\/pixeldigitalagency.com\/clients\/plasmaseq\/?page_id=423"},"modified":"2025-02-03T10:15:34","modified_gmt":"2025-02-03T10:15:34","slug":"technology","status":"publish","type":"page","link":"https:\/\/www.ncgmus.com\/plasmaseq\/technology\/","title":{"rendered":"Technology"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t
You are here:<\/div>
  1. Home<\/span><\/a><\/li>
  2. Page<\/span><\/li><\/ol>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
    \n\t\t\t\t\t
    \n\t\t
    \n\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t

    Comparison with Conventional Testing<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t\t\t
      \n\t\t\t\t\t\t\t
    • \n\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t<\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\tBiallelic 1p del<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
      \n\t\t\t\t
      \n\t\t\t\t\t\t\t

      1p deletions involving the CDKN2C gene are critical in defining risk in multiple myeloma. Though FISH is able to identify multiple myeloma 1p deletions, it is often challenging for it to detect bi-allelic deletions which indicate deletions of both copies of the gene. This is especially important when small portions of this gene are deleted. It is anticipated that almost *** percentage of bi allelic deletions may be missed by FISH based on available data.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

      \n\t\t\t\t
      \n\t\t\t\t\t
        \n\t\t\t\t\t\t\t
      • \n\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t<\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\tSmall 17p dels<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
        \n\t\t\t\t
        \n\t\t\t\t\t\t\t

        TP53 plays a major role in determining risk stratification in multiple myeloma. Historically only the 17p deletion has been used for this assessment . However PlasmaSEQ now classifies this at a dramatically improved resolution with the ability to detect small \u2018multi-exonic\u2019 deletions as well as the ability to detect single base pair level changes which have never been available before in a single assay.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

        \n\t\t\t\t
        \n\t\t\t\t\t
          \n\t\t\t\t\t\t\t
        • \n\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t<\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\tIgH breakpoint<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
          \n\t\t\t\t
          \n\t\t\t\t\t\t\t

          For a long time, it has been well known that the exact breakpoint of the IgH rearrangement in translocations such as 4:14 and 14:16 affects outcomes. PlasmaSEQ finally provides this information for every patient while also helping researchers better determine how best to determine therapy and design clinical trials.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

          \n\t\t\t\t
          \n\t\t\t\t\t
            \n\t\t\t\t\t\t\t
          • \n\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t<\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\tImmunotherapy targets- BCMA, GPRC5D, APRIL (v2)<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
            \n\t\t\t\t
            \n\t\t\t\t\t\t\t

            With the advent of immunotherapies, it is imperative that we have assays that can work for critical genes like BCMA, GPRC5D and APRIL. Plasmaseq V2 incorporates all of these targets and serves the critical need of being able to detect abnormalities in these genes at a very low plasma cell content.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

            \n\t\t\t\t
            \n\t\t\t\t
            \n\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

            You are here: Home Page Comparison with Conventional Testing Biallelic 1p del 1p deletions involving the CDKN2C gene are critical in defining risk in multiple myeloma. Though FISH is able to identify multiple myeloma 1p deletions, it is often challenging for it to detect bi-allelic deletions which indicate deletions of both copies of the gene.…<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"footnotes":""},"class_list":["post-423","page","type-page","status-publish","hentry"],"yoast_head":"\nPlasmaSeq Technology \u2013 Cutting-Edge NGS for Myeloma<\/title>\n<meta name=\"description\" content=\"Discover the advanced NGS technology behind PlasmaSeq, enabling precise detection of mutations, CNVs, and IGH translocations in Multiple Myeloma.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ncgmus.com\/plasmaseq\/technology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PlasmaSeq Technology \u2013 Cutting-Edge NGS for Myeloma\" \/>\n<meta property=\"og:description\" content=\"Discover the advanced NGS technology behind PlasmaSeq, enabling precise detection of mutations, CNVs, and IGH translocations in Multiple Myeloma.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ncgmus.com\/plasmaseq\/technology\/\" \/>\n<meta property=\"og:site_name\" content=\"Plasmaseq\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-03T10:15:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pixeldigitalagency.com\/clients\/plasmaseq\/wp-content\/uploads\/2024\/10\/responsive-banner.webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ncgmus.com\/plasmaseq\/technology\/\",\"url\":\"https:\/\/www.ncgmus.com\/plasmaseq\/technology\/\",\"name\":\"PlasmaSeq Technology \u2013 Cutting-Edge NGS for Myeloma\",\"isPartOf\":{\"@id\":\"https:\/\/www.ncgmus.com\/plasmaseq\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ncgmus.com\/plasmaseq\/technology\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ncgmus.com\/plasmaseq\/technology\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pixeldigitalagency.com\/clients\/plasmaseq\/wp-content\/uploads\/2024\/10\/responsive-banner.webp\",\"datePublished\":\"2024-10-23T13:06:05+00:00\",\"dateModified\":\"2025-02-03T10:15:34+00:00\",\"description\":\"Discover the advanced NGS technology behind PlasmaSeq, enabling precise detection of mutations, CNVs, and IGH translocations in Multiple Myeloma.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ncgmus.com\/plasmaseq\/technology\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ncgmus.com\/plasmaseq\/technology\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ncgmus.com\/plasmaseq\/technology\/#primaryimage\",\"url\":\"https:\/\/pixeldigitalagency.com\/clients\/plasmaseq\/wp-content\/uploads\/2024\/10\/responsive-banner.webp\",\"contentUrl\":\"https:\/\/pixeldigitalagency.com\/clients\/plasmaseq\/wp-content\/uploads\/2024\/10\/responsive-banner.webp\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ncgmus.com\/plasmaseq\/technology\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ncgmus.com\/plasmaseq\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ncgmus.com\/plasmaseq\/#website\",\"url\":\"https:\/\/www.ncgmus.com\/plasmaseq\/\",\"name\":\"Plasmaseq\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ncgmus.com\/plasmaseq\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ncgmus.com\/plasmaseq\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ncgmus.com\/plasmaseq\/#organization\",\"name\":\"Plasmaseq\",\"url\":\"https:\/\/www.ncgmus.com\/plasmaseq\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ncgmus.com\/plasmaseq\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ncgmus.com\/plasmaseq\/wp-content\/uploads\/2024\/10\/logo-plasma-1.webp\",\"contentUrl\":\"https:\/\/www.ncgmus.com\/plasmaseq\/wp-content\/uploads\/2024\/10\/logo-plasma-1.webp\",\"width\":210,\"height\":45,\"caption\":\"Plasmaseq\"},\"image\":{\"@id\":\"https:\/\/www.ncgmus.com\/plasmaseq\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PlasmaSeq Technology \u2013 Cutting-Edge NGS for Myeloma","description":"Discover the advanced NGS technology behind PlasmaSeq, enabling precise detection of mutations, CNVs, and IGH translocations in Multiple Myeloma.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ncgmus.com\/plasmaseq\/technology\/","og_locale":"en_US","og_type":"article","og_title":"PlasmaSeq Technology \u2013 Cutting-Edge NGS for Myeloma","og_description":"Discover the advanced NGS technology behind PlasmaSeq, enabling precise detection of mutations, CNVs, and IGH translocations in Multiple Myeloma.","og_url":"https:\/\/www.ncgmus.com\/plasmaseq\/technology\/","og_site_name":"Plasmaseq","article_modified_time":"2025-02-03T10:15:34+00:00","og_image":[{"url":"https:\/\/pixeldigitalagency.com\/clients\/plasmaseq\/wp-content\/uploads\/2024\/10\/responsive-banner.webp","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ncgmus.com\/plasmaseq\/technology\/","url":"https:\/\/www.ncgmus.com\/plasmaseq\/technology\/","name":"PlasmaSeq Technology \u2013 Cutting-Edge NGS for Myeloma","isPartOf":{"@id":"https:\/\/www.ncgmus.com\/plasmaseq\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ncgmus.com\/plasmaseq\/technology\/#primaryimage"},"image":{"@id":"https:\/\/www.ncgmus.com\/plasmaseq\/technology\/#primaryimage"},"thumbnailUrl":"https:\/\/pixeldigitalagency.com\/clients\/plasmaseq\/wp-content\/uploads\/2024\/10\/responsive-banner.webp","datePublished":"2024-10-23T13:06:05+00:00","dateModified":"2025-02-03T10:15:34+00:00","description":"Discover the advanced NGS technology behind PlasmaSeq, enabling precise detection of mutations, CNVs, and IGH translocations in Multiple Myeloma.","breadcrumb":{"@id":"https:\/\/www.ncgmus.com\/plasmaseq\/technology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ncgmus.com\/plasmaseq\/technology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ncgmus.com\/plasmaseq\/technology\/#primaryimage","url":"https:\/\/pixeldigitalagency.com\/clients\/plasmaseq\/wp-content\/uploads\/2024\/10\/responsive-banner.webp","contentUrl":"https:\/\/pixeldigitalagency.com\/clients\/plasmaseq\/wp-content\/uploads\/2024\/10\/responsive-banner.webp"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ncgmus.com\/plasmaseq\/technology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ncgmus.com\/plasmaseq\/"},{"@type":"ListItem","position":2,"name":"Technology"}]},{"@type":"WebSite","@id":"https:\/\/www.ncgmus.com\/plasmaseq\/#website","url":"https:\/\/www.ncgmus.com\/plasmaseq\/","name":"Plasmaseq","description":"","publisher":{"@id":"https:\/\/www.ncgmus.com\/plasmaseq\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ncgmus.com\/plasmaseq\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ncgmus.com\/plasmaseq\/#organization","name":"Plasmaseq","url":"https:\/\/www.ncgmus.com\/plasmaseq\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ncgmus.com\/plasmaseq\/#\/schema\/logo\/image\/","url":"https:\/\/www.ncgmus.com\/plasmaseq\/wp-content\/uploads\/2024\/10\/logo-plasma-1.webp","contentUrl":"https:\/\/www.ncgmus.com\/plasmaseq\/wp-content\/uploads\/2024\/10\/logo-plasma-1.webp","width":210,"height":45,"caption":"Plasmaseq"},"image":{"@id":"https:\/\/www.ncgmus.com\/plasmaseq\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.ncgmus.com\/plasmaseq\/wp-json\/wp\/v2\/pages\/423","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ncgmus.com\/plasmaseq\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ncgmus.com\/plasmaseq\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ncgmus.com\/plasmaseq\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ncgmus.com\/plasmaseq\/wp-json\/wp\/v2\/comments?post=423"}],"version-history":[{"count":28,"href":"https:\/\/www.ncgmus.com\/plasmaseq\/wp-json\/wp\/v2\/pages\/423\/revisions"}],"predecessor-version":[{"id":914,"href":"https:\/\/www.ncgmus.com\/plasmaseq\/wp-json\/wp\/v2\/pages\/423\/revisions\/914"}],"wp:attachment":[{"href":"https:\/\/www.ncgmus.com\/plasmaseq\/wp-json\/wp\/v2\/media?parent=423"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}